China Agrees To Erase Import Drugs Approval Backlog Soon
This article was originally published in PharmAsia News
Pharma and device makers in the United States can breathe easier as China promises to expedite its regulatory process to usher in quicker market access within two to three years.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.